CINECA IRIS Institutional Research Information System

CECCHI, Irene
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.448
EU - Europa 2.535
AS - Asia 1.547
SA - Sud America 269
AF - Africa 36
OC - Oceania 29
Continente sconosciuto - Info sul continente non disponibili 6
Totale 7.870
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.196
IT - Italia 825
CN - Cina 701
ES - Italia 321
IE - Irlanda 224
DE - Germania 222
SG - Singapore 208
JP - Giappone 181
GB - Regno Unito 154
FR - Francia 153
MX - Messico 124
CA - Canada 110
SE - Svezia 108
BR - Brasile 95
IN - India 90
AR - Argentina 66
NL - Olanda 60
VN - Vietnam 60
ID - Indonesia 52
PL - Polonia 49
UA - Ucraina 49
CO - Colombia 48
RO - Romania 45
RU - Federazione Russa 44
FI - Finlandia 43
HK - Hong Kong 42
PT - Portogallo 40
TW - Taiwan 37
TR - Turchia 35
AU - Australia 28
BE - Belgio 28
GR - Grecia 28
CH - Svizzera 25
KR - Corea 25
IL - Israele 22
IR - Iran 22
DK - Danimarca 21
AT - Austria 19
CL - Cile 18
EC - Ecuador 16
PE - Perù 15
RS - Serbia 15
PH - Filippine 13
EG - Egitto 12
HU - Ungheria 12
TH - Thailandia 12
SA - Arabia Saudita 11
MA - Marocco 10
NO - Norvegia 10
CZ - Repubblica Ceca 8
DZ - Algeria 8
SI - Slovenia 7
CR - Costa Rica 6
EU - Europa 6
MY - Malesia 6
PK - Pakistan 5
VE - Venezuela 5
BG - Bulgaria 4
BO - Bolivia 4
HR - Croazia 4
MT - Malta 4
PA - Panama 4
SK - Slovacchia (Repubblica Slovacca) 4
AE - Emirati Arabi Uniti 3
IQ - Iraq 3
LT - Lituania 3
MO - Macao, regione amministrativa speciale della Cina 3
AM - Armenia 2
BD - Bangladesh 2
DO - Repubblica Dominicana 2
GE - Georgia 2
JE - Jersey 2
JO - Giordania 2
LK - Sri Lanka 2
LV - Lettonia 2
SV - El Salvador 2
TN - Tunisia 2
UZ - Uzbekistan 2
BN - Brunei Darussalam 1
BY - Bielorussia 1
CU - Cuba 1
ET - Etiopia 1
GT - Guatemala 1
LB - Libano 1
MK - Macedonia 1
NG - Nigeria 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
OM - Oman 1
QA - Qatar 1
SC - Seychelles 1
SR - Suriname 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
ZA - Sudafrica 1
Totale 7.870
Salva come PNG Salva come JPEG
Città #
Chandler 389
Ann Arbor 253
Fairfield 234
Dublin 222
Redwood City 217
Beijing 189
Torino 162
Singapore 160
Ashburn 155
Turin 138
Sesto San Giovanni 117
Woodbridge 107
Wilmington 106
Houston 98
Cambridge 77
Seattle 70
Medford 68
Nyköping 66
Munich 61
Princeton 60
Madrid 56
Shanghai 55
Jakarta 52
New York 50
Tokyo 46
Montréal 44
Dearborn 38
Dong Ket 38
Milan 35
Rome 34
Córdoba 33
Hangzhou 33
Mexico City 33
Paris 32
Barcelona 30
San Diego 30
Chicago 27
Helsinki 26
Jacksonville 26
Buenos Aires 25
Mcallen 24
Guangzhou 23
Boston 22
Pisa 22
Nanjing 20
Athens 19
Wuhan 19
Hebei 18
Los Angeles 18
São Paulo 18
Taipei 18
Brussels 17
Hong Kong 17
Berlin 16
Santa Clara 16
Santiago 16
Zhengzhou 16
Chengdu 15
Lisbon 15
Mumbai 15
Warsaw 15
Amsterdam 14
Guiyang 14
Kunming 14
Medellín 14
Munro 14
Villeurbanne 14
Birmingham 13
Bogotá 13
Hyderabad 13
Ankara 12
London 12
Sevilla 12
Washington 12
Belgrade 11
Changsha 11
Coyoacán 11
Delhi 11
Falls Church 11
Frankfurt am Main 11
Mexico 11
Ottawa 11
San Francisco 11
Santander 11
Seoul 11
Toronto 11
Valencia 11
Bucharest 10
Cuenca 10
Hefei 10
Lima 10
Shenyang 10
Bologna 9
Budapest 9
Central District 9
Jinan 9
Norwalk 9
Seville 9
Shenzhen 9
Vienna 9
Totale 4.507
Salva come PNG Salva come JPEG
Nome #
Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome 574
The adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) for risk stratification in young APS patients with acute myocardial infarction 508
Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence 505
Pregnancy outcomes in mixed connective tissue disease: a multicentre study 417
Clinical utility of the global anti-phospholipid syndrome score for risk stratification: A pooled analysis 389
Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab 338
The risk of ischaemic stroke in primary APS patients: a prospective study 301
Evaluation of novel assays for the detection of autoantibodies in antiphospholipid syndrome 260
Treatment of antiphospholipid syndrome 258
Long-term effect of B-cells depletion alone as rescue therapy for severe thrombocytopenia in primary antiphospholipid syndrome 232
Thermography in systemic sclerosis patients and other rheumatic diseases: Diagnosis, disease activity assessment, and therapeutic monitoring 218
Translational validation of the Global Antiphospholipid Syndrome Score in patients with thrombotic APS 194
Neutrophils: Novel key players in Rheumatoid Arthritis. Current and future therapeutic targets 172
Pregnancy success rate and response to heparins and/or aspirin differ in women with antiphospholipid antibodies according to their Global AntiphosPholipid Syndrome Score 170
Reliability of lupus anticoagulant and anti-phosphatidylserine/prothrombin autoantibodies in antiphospholipid syndrome: A multicenter study 148
Ubiquinol effects on antiphospholipid syndrome prothrombotic profile: A randomized, placebo-controlled trial 148
An agent-to-agent real life comparison study of tocilizumab versus abatacept in giant cell arteritis 145
Circulating microRNAs as biomarkers of disease and typification of the atherothrombotic status in antiphospholipid syndrome 122
Antiphospholipid antibodies negativization: Time for testing for non-criteria aPL? 116
Prevalence and Thrombotic Risk Assessment of Anti-beta(2) Glycoprotein I Domain I Antibodies: A Systematic Review 114
Disease evolution in a long-term follow-up of 104 undifferentiated connective tissue disease patients 103
Clinical manifestations in patients with antiphospholipid antibodies: Beyond thrombosis and pregnancy loss 102
Tailoring tofacitinib oral therapy in rheumatoid arthritis: The TuTORApp—a usability study 93
Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19 93
Anti-beta-2-glycoprotein I domain 1 identifies antiphospholipid antibodies-related injuries in patients with concomitant lupus nephritis 86
Early restoration of immune and vascular phenotypes in systemic lupus erythematosus and rheumatoid arthritis patients after B cell depletion 84
Quality of life in patients with antiphospholipid antibodies differs according to antiphospholipid syndrome damage index (DIAPS) 84
IgG Anti-high-Density Lipoproteins Antibodies Discriminate Between Arterial and Venous Events in Thrombotic Antiphospholipid Syndrome Patients 83
Improving the clinical accuracy in patients with antiphospholipid antibodies using anti-phosphatidylserine/prothrombin and anti-beta2 glycoprotein I domain and particle-based multi-analyte technology 82
Identifying phenotypes of patients with antiphospholipid antibodies: results from a cluster analysis in a large cohort of patients 79
Prevalence of Antiphospholipid Antibodies Negativisation in Patients with Antiphospholipid Syndrome: A Long-Term Follow-Up Multicentre Study 79
Impact of the new 2019 EULAR/ACR classification criteria for Systemic Lupus Erythematosus in a multicenter cohort study of 133 women with undifferentiated connective tissue disease 78
Antiphospholipid Syndrome Is Still a Rare Disease—Estimated Prevalence in the Piedmont and Aosta Valley Regions of Northwest Italy: Comment on the Article by Duarte-García et al 77
Immunotherapies in phase II and III trials for the treatment of systemic lupus erythematosus 69
Clinical Delphi on aPL Negativization: Report from the APS Study Group of the Italian Society for Rheumatology (SIR-APS) 68
The potential role of SLE-key test in identifying patients with Systemic Lupus Erythematosus: Results from a prospective, real-world experience 67
Antiphosphatidylserine/Prothrombin Antibodies: An Update on Their Association with Clinical Manifestations of Antiphospholipid Syndrome 65
Genetic factors in antiphospholipid syndrome: Preliminary experience with whole exome sequencing 64
Reducing the diagnostic delay in Antiphospholipid Syndrome over time: a real world observation 64
The prevalence of antiphospholipid antibodies in women with late pregnancy complications and low-risk for chromosomal abnormalities 62
Utilizing type I interferon expression in the identification of antiphospholipid syndrome subsets 62
Cerebrovascular events in patients with isolated anti-phosphatidyl-serine/prothrombin antibodies 58
ASIA Syndrome Following Breast Implant Placement 56
Circulating microRNAs as potential biomarkers for monitoring the response to in vivo treatment with Rituximab in systemic lupus erythematosus patients 55
16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome 54
Incidence of a First Thrombo-Embolic Event in Patients With Systemic Lupus Erythematosus and Anti-phosphatidylserine/prothrombin Antibodies: A Prospective Study 53
A 3-Year Observational Study of Patients with Progressive Systemic Sclerosis Treated with an Intensified B Lymphocyte Depletion Protocol: Clinical and Immunological Response 53
Open-label, prospective, phase II descriptive pilot trial of belimumab therapy for refractory and/or non-criteria manifestations of antiphospholipid syndrome: study protocol 48
Endothelial dysfunction and cardiovascular risk in lupus nephritis: new roles for old players? 47
A multicentre study of 244 pregnancies in undifferentiated connective tissue disease: maternal/fetal outcomes and disease evolution 47
"How we treat" clinical dilemmas in antiphospholipid syndrome: A case-based approach 44
Safety and tolerability of mRNA COVID-19 vaccines in people with antiphospholipid antibodies 43
Validation of the particle-based multi-analyte technology for detection of anti-phosphatidylserine/ prothrombin antibodies 39
Prevalence and significance of anti-phosphatidylserine antibodies: A pooled analysis in 5992 patients 37
Circulating immune-complexes of IgG/IgM bound to B2-glycoprotein-I associated with complement consumption and thrombocytopenia in antiphospholipid syndrome 36
Multifocal avascular osteonecrosis despite appropriate anticoagulation therapy in a patient with systemic lupus erythematosus and antiphospholipid syndrome 33
Detection of Autoantibodies in Saliva as New Avenue for the Diagnosis and Management of Autoimmune Patients 30
Assessing the cardiovascular risk in patients with systemic lupus erythematosus: QRISK and GAPSS scores head-to-head 29
Disease activity at conception predicts lupus flare up to two years after birth: A multicentre long term follow-up study 29
Thrombin generation assay and lupus anticoagulant synergically distinguish populations of patients with antiphospholipid antibodies 28
Daratumumab monotherapy for refractory lupus nephritis 26
The global antiphospholipid syndrome score in women with systemic lupus erythematosus and adverse pregnancy outcomes 26
Dickkopf Homolog 3 (DKK3) as a Prognostic Marker in Lupus Nephritis: A Prospective Monocentric Experience 25
Renal Fibrosis in Lupus Nephritis 23
Finding the Needle in the Haystack: Serological and Urinary Biomarkers in Behçet’s Disease: A Systematic Review 21
Tailoring Tofacitinib Oral Therapy in Rheumatoid Arthritis: The TuTOR App 20
Serum Biomarkers of Renal Fibrosis: A Systematic Review 19
2023 ACR/EULAR classification criteria in existing research cohorts: an international study 17
New Frontiers in Autoimmune Diagnostics: A Systematic Review on Saliva Testing 16
Reply to comment on: Disease evolution in a long-term follow-up of 104 undifferentiated connective tissue disease patients 16
Assessing the steroid-sparing effect of biological agents in randomized controlled trials for lupus: a scoping review 13
Defective glucose and lipid metabolism in rheumatoid arthritis is determined by chronic inflammation in metabolic tissues 13
Complement levels during the first trimester predict disease flare and adverse pregnancy outcomes in systemic lupus erythematosus: A network meta-analysis on 532 pregnancies 12
Clinical-Pathological Characteristics of Renal Injuries Identify Different Clusters in Patients With Antiphospholipid Antibodies 10
Clinical Delphi on aPL Negativization: Report from the APS Study Group of the Italian Society for Rheumatology (SIR-APS) (vol 122, pg 1612, 2022) 9
Thrombosis and APS: Lessons Learned from Another Black Swan Tale 8
Identifying subsets of patients with undifferentiated connective tissue disease: Results from a prospective, real-world experience using particle-based multi-analyte technology 8
Impaired microRNA processing in neutrophils from rheumatoid arthritis patients confers their pathogenic profile. Modulation by biological therapies 8
Safety and efficacy of pre-exposure prophylaxis with tixagevimab/cilgavimab (Evusheld) in patients with glomerular diseases who received rituximab 8
Chasing the Zebra: a case of membranous-like Glomerulopathy with SSA/RO52 deposits and no overt connective tissue disease 7
Pursuing appropriateness in antiphospholipid antibodies testing: Feasibility study with a reflex test approach for anti-β2GPI I domain 5
Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases 5
Integrated Analysis of Serological Biomarkers for the Early Detection of Pregnancy Morbidity in Connective Tissue Diseases 2
Pediatric Presentation of Antiphospholipid Syndrome: A Review of Recent Literature With Estimation of Local Prevalence 2
Totale 8.111
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.983
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.983
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020983 0 0 0 109 91 105 138 110 132 102 115 81
2020/20211.237 98 83 149 144 133 74 76 68 95 114 78 125
2021/20221.426 83 111 110 111 155 118 114 93 100 81 158 192
2022/20231.713 153 146 90 121 146 342 125 141 160 70 123 96
2023/20241.636 156 159 130 99 151 134 118 124 44 136 121 264
2024/2025501 107 182 143 69 0 0 0 0 0 0 0 0
Totale 8.111